

# CD287 - Carcinogens and Mutagens – Revision of limit values in EH40/2005 “Workplace Exposure Limits”

## Questionnaire

Q.1 The findings of the impact assessment (IA) suggest there is unlikely to be any significant additional costs to business from complying with the revised workplace exposure limits (WELs) following implementation of Phase 1 of the Carcinogens and Mutagens Directive (CMD). Based on your knowledge and understanding of the changes, do you agree or disagree with the IA finding?

* Agree
* Disagree (please see below)
* Unsure/don’t know

If you ‘disagree’ with the IA finding, please detail why and supply any information or evidence supporting your view (e.g. which substance[s] your response relates to, the type[s], number and cost of additional control measures required, etc.).

Q.2 The new WELs will be introduced in an update of the HSE publication EH40/2005 (<http://www.hse.gov.uk/pubns/priced/eh40.pdf>). Do you agree that this is the most appropriate way of updating the WELs?

* Yes
* No (please see below)
* Unsure/don’t know

If you answered ‘no’, please detail why and what would be a more appropriate way of updating the WELs